35,100 Medtronic PLC $MDT Shares Acquired by Soltis Investment Advisors LLC

Key Points

• Soltis Investment Advisors increased its Medtronic stake by 26.5%, acquiring 35,100 shares to bring its holdings to 167,746 shares valued at approximately $14.5 million. Institutional investors collectively own 82.06% of the company.
• Medtronic reported quarterly EPS of $1.45 and revenue of $9.76 billion, exceeding analyst expectations, while revenue grew 13.7% year over year. The company also pays a quarterly dividend of $0.72 per share, equivalent to a 3.0% annual yield.
• Analysts maintain a generally positive outlook, with a consensus rating of “Moderate Buy” and an average price target of $102.88 versus the stock’s reported $96.92 price. However, company insiders sold 61,903 shares worth approximately $5.9 million over the past three months.

Soltis Investment Advisors LLC boosted its stake in Medtronic PLC (NYSE:MDT - Free Report) by 26.5% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 167,746 shares of the medical technology company's stock after buying an additional 35,100 shares during the period. Medtronic makes up 0.7% of Soltis Investment Advisors LLC's portfolio, making the stock its 22nd largest holding. Soltis Investment Advisors LLC's holdings in Medtronic were worth $14,475,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Activest Wealth Management boosted its holdings in shares of Medtronic by 470.9% during the third quarter. Activest Wealth Management now owns 314 shares of the medical technology company's stock worth $27,000 after acquiring an additional 259 shares during the period. IAG Wealth Partners LLC bought a new position in shares of Medtronic during the second quarter worth approximately $30,000. Pin Oak Investment Advisors Inc. bought a new position in shares of Medtronic during the second quarter worth approximately $32,000. Community Bank N.A. bought a new position in shares of Medtronic during the second quarter worth approximately $33,000. Finally, Core Capital Management & Research inc. acquired a new stake in Medtronic during the 2nd quarter worth approximately $33,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Medtronic Stock Up 2.3%

NYSE MDT opened at $96.92 on Friday. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The company has a market cap of $123.98 billion, a price-to-earnings ratio of 16.57, a PEG ratio of 2.22 and a beta of 0.55. The company has a 50 day moving average of $91.62 and a 200-day moving average of $88.35. Medtronic PLC has a 1-year low of $73.31 and a 1-year high of $106.33.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.39 by $0.06. Medtronic had a return on equity of 14.78% and a net margin of 13.93%. The business had revenue of $9.76 billion for the quarter, compared to the consensus estimate of $9.55 billion. During the same quarter in the prior year, the business posted $1.26 earnings per share. The firm's quarterly revenue was up 13.7% compared to the same quarter last year. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. On average, equities research analysts expect that Medtronic PLC will post 5.98 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, October 16th. Stockholders of record on Friday, September 25th were given a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date was Friday, September 25th. Medtronic's dividend payout ratio is presently 70.94%.

Insider Activity

In other news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the sale, the executive vice president directly owned 42,186 shares of the company's stock, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Michael Marinaro sold 10,420 shares of the firm's stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the transaction, the executive vice president owned 105,916 shares in the company, valued at $10,167,936. The trade was a 8.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders sold 61,903 shares of company stock worth $5,889,203. 0.27% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on MDT shares. TD Cowen restated a "buy" rating and issued a $110.00 price target on shares of Medtronic in a research note on Wednesday, September 30th. Royal Bank Of Canada reiterated an "outperform" rating and set a $118.00 price objective on shares of Medtronic in a research report on Wednesday, September 2nd. Evercore set a $105.00 target price on Medtronic in a report on Monday, July 6th. Truist Financial reissued a "hold" rating and issued a $99.00 target price (up from $86.00) on shares of Medtronic in a research report on Wednesday, September 2nd. Finally, Barclays upgraded shares of Medtronic to a "hold" rating in a research note on Wednesday, October 7th. Eighteen equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $102.88.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Exchange-traded funds purchased approximately $18 million of Medtronic shares on October 26, providing a potentially supportive source of demand and signaling institutional interest. ETFs Bought $18.0 Million of Medtronic
• Positive Sentiment: Analyst commentary highlighted Medtronic’s broader growth opportunities and described its valuation as attractive, supporting the case for the stock as a relatively defensive medical-technology investment. Medtronic: Broader Growth, Attractive Valuation
• Positive Sentiment: Medtronic gained even as the overall market dipped, suggesting investors viewed the company’s defensive characteristics and medical-device exposure favorably. Why the Market Dipped But Medtronic Gained Today
• Neutral Sentiment: Upcoming second-quarter fiscal 2027 results are drawing attention. Analysts reportedly expect a low-single-digit decline in profit, making management’s guidance and performance in key growth businesses important near-term catalysts. Medtronic’s Q2 2027 Earnings: What to Expect
• Neutral Sentiment: Comparisons with other medical-device companies, including STERIS, and reviews of Medtronic’s historical shareholder returns provide context but do not identify a new fundamental catalyst. What Have Medtronic Stock Holders Really Earned?

Medtronic Company Profile

Medtronic plc NYSE: MDT is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company's offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.